New cell therapy GT719 targets tough blood cancers in early trial
NCT ID NCT06948981
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial is testing an experimental cell therapy called GT719 in 46 adults with relapsed or treatment-resistant B-cell lymphoma or leukemia that tests positive for CD19. The study aims to see if the treatment is safe and how well it works. Participants receive a single injection of GT719 and are monitored for side effects and cancer response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GT719 injection (a type of cell therapy targeting CD19-positive cancer cells)
What this could lead to
If successful, this could offer a new treatment option for patients with hard-to-treat B-cell blood cancers that have not responded to standard therapies.
What could go wrong
This is an early-phase trial with only 46 participants, so results may not apply broadly. Cell therapies can cause serious side effects like cytokine release syndrome or nervous system problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
RECRUITINGTianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact